Immune-stimulating drug before surgery shows promise in early-stage pancreatic cancer

PHILADELPHIA–Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania. Changing the microenvironment from so-called T cell “poor” to T cell…

Details

The impact of chemotherapy on immune cells in the tumor microenvironment

Research from Queen Mary University of London has revealed novel insights into the effects of chemotherapy on the tumour microenvironment (TME). The study, published today in Cancer Immunology Research, a journal of the American Association for Cancer Research, found that chemotherapy enhances the anti-tumour actions of immune cells within the TME and their ability to…

Details

Blood Clots Linked to AZ Vaccine Stem From Rare Antibody Reaction

The antibodies led to a condition called thrombotic thrombocytopenia, which caused both clotting and abnormal bleeding. The researchers suggested naming the newly identified version in these patients “vaccine-induced immune thrombotic thrombocytopenia,” or VITT. Various theories have been offered by scientists as to what touches off the immune reaction. The AstraZeneca vaccine employs a chimpanzee adenovirus…

Details